Back

Nationwide estimates of SARS-CoV-2 infection fatality rates and numbers needed to vaccinate for SARS-CoV-2 vaccines in 2024 in Austria

Riedmann, U.; Sprenger, M.; Ioannidis, J.; Pilz, S.

2025-08-24 infectious diseases
10.1101/2025.08.20.25334029 medRxiv
Show abstract

BackgroundPost-pandemic years are characterized by widespread previous population immunisation against COVID-19. Whether and for whom SARS-CoV-2 vaccinations are still justified is unclear. We use nationwide estimates of IFR and literature derived estimates of vaccine effectiveness (VE) to calculate numbers needed to vaccinate to prevent one COVID-19 death (NNV) and for one life-year saved (LYS) in Austria in 2024. MethodsIn this retrospective analysis we calculate SARS-CoV-2 IFR during 2024 in Austria according to previously published wastewater-based infection estimates and available mortality data. Using literature derived VE estimates we calculate NNV to prevent one COVID-19 death and for one LYS in strata according to age groups, nursing home residency and vaccination in 2024. We repeat analyses with sensitivity range values of parameters. ResultsIn 2024, total IFR was 0.048%. NNV (LYS) in the age groups 0-19, 20-39, 40-59, 60-74 and 75-84 years were very high: e.g. 5,497,526 (151,570), 2,432,498 (92,614), 415,714 (24,777), 35,925 (3,748), and 4,882 (1,009), respectively, in community dwellers. In the 85+ years age group, IFRs of unvaccinated/vaccinated were 0.91%/0.77% for community dwellers, and 1.22%/1.04% for nursing home residents. The 85+ year age group had NNV estimates of 1,215 and 907 (LYS: 525 and 1,896) in community dweller and nursing home residents, respectively. Sensitivity analyses yielded LYS<1,000 only under some favourable assumptions in the 75-84 and 85+ years old age strata. ConclusionsIn 2024 SARS-CoV-2 IFR was low and NNV and LYS of COVID-19 vaccinations correspondingly non-favourably high, even for very old individuals.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Eurosurveillance
80 papers in training set
Top 0.1%
10.2%
2
The Lancet Regional Health - Europe
32 papers in training set
Top 0.1%
8.0%
3
Vaccine
189 papers in training set
Top 0.5%
7.0%
4
Nature Communications
4913 papers in training set
Top 34%
4.7%
5
PLOS Medicine
98 papers in training set
Top 1.0%
3.8%
6
Age and Ageing
27 papers in training set
Top 0.2%
3.6%
7
eClinicalMedicine
55 papers in training set
Top 0.1%
3.5%
8
The Lancet Infectious Diseases
71 papers in training set
Top 0.8%
3.5%
9
PLOS ONE
4510 papers in training set
Top 41%
3.5%
10
BMC Public Health
147 papers in training set
Top 2%
3.5%
50% of probability mass above
11
Journal of the American Medical Directors Association
13 papers in training set
Top 0.1%
3.0%
12
Journal of Infection
71 papers in training set
Top 0.6%
3.0%
13
BMC Medicine
163 papers in training set
Top 2%
2.7%
14
Scientific Reports
3102 papers in training set
Top 44%
2.7%
15
BMC Infectious Diseases
118 papers in training set
Top 2%
2.0%
16
Clinical Microbiology and Infection
60 papers in training set
Top 0.5%
1.8%
17
Clinical Infectious Diseases
231 papers in training set
Top 3%
1.7%
18
BMJ
49 papers in training set
Top 0.6%
1.7%
19
International Journal of Infectious Diseases
126 papers in training set
Top 2%
1.6%
20
European Journal of Public Health
20 papers in training set
Top 0.5%
1.6%
21
BMJ Open
554 papers in training set
Top 10%
1.5%
22
Public Health
34 papers in training set
Top 0.8%
1.5%
23
Journal of Epidemiology and Community Health
32 papers in training set
Top 0.4%
1.5%
24
The Lancet Healthy Longevity
11 papers in training set
Top 0.1%
1.3%
25
Infectious Diseases
14 papers in training set
Top 0.1%
1.2%
26
International Journal of Epidemiology
74 papers in training set
Top 2%
1.1%
27
Human Vaccines & Immunotherapeutics
25 papers in training set
Top 0.6%
0.9%
28
JAMA Network Open
127 papers in training set
Top 3%
0.9%
29
The Lancet
16 papers in training set
Top 0.6%
0.9%
30
Vaccines
196 papers in training set
Top 2%
0.9%